NewportNativeMD, Inc.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis5 trials
• COPD3 trials
• Asthma2 trials
• Systemic sclerosis (scleroderma)1 trial

Phase

• Phase 26 trials
• Phase 34 trials
• Phase 2/31 trial

Status

• Recruiting8 trials
• Active, not recruiting1 trial
• Completed1 trial
• Enrolling by invitation1 trial

Lead sponsor

• United Therapeutics3 trials
• Eli Lilly and Company2 trials
• Pfizer2 trials
• Altesa Biosciences, Inc.1 trial
• Mediar Therapeutics1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

  Contact: Ryan Klein (principal investigator)

• Recruiting

  Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

  NCT07671911· Phase 3· Trevi Therapeutics· Source

  Contact: Paula Buckley

• Recruiting

  Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

  NCT07610395· Phase 2· Altesa Biosciences, Inc.· Source

  Contact: NewportNativeMD, Inc.

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· Phase 2· Mediar Therapeutics· Source

  Contact: Jennifer Gonzolez

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

  Contact: Ryan Klein (principal investigator)

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

  Contact: Grace Harvey

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Asthma2 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source